Surgery
Volume 147, Issue 3 , Pages 424-431 , March 2010

Prognostic factors and the therapeutic strategy for patients with bone metastasis from differentiated thyroid carcinoma

  • Yorihisa Orita, MD, PhD

      Affiliations

    • Department of Otolaryngology Head and Neck Surgery, Okayama Saiseikai General Hospital, Okayama, Japan
    • Corresponding Author InformationReprint requests: Yorihisa Orita, MD, PhD, Department of Otolaryngology Head and Neck Surgery, Okayama Saiseikai General Hospital, 1-17-18, Ifuku-Cho, Okayama 700-8511, Japan.
    • ,
  • Iwao Sugitani, MD, PhD

      Affiliations

    • Division of Head and Neck, Cancer Institute Hospital, Tokyo, Japan
    • ,
  • Masaaki Matsuura, PhD

      Affiliations

    • Department of Cancer Genomics, Cancer Institute of the Japanese Foundation for Cancer Research, Tokyo, Japan
    • ,
  • Masaru Ushijima, MSc

      Affiliations

    • Department of Bioinformatics of Genome Center, Cancer Institute of the Japanese Foundation for Cancer Research, Tokyo, Japan
    • ,
  • Kiyoaki Tsukahara, MD, PhD

      Affiliations

    • Department of Otolaryngology, Tokyo Medical University, Tokyo, Japan
    • ,
  • Yoshihide Fujimoto, MD, PhD

      Affiliations

    • Division of Head and Neck, Cancer Institute Hospital, Tokyo, Japan
    • ,
  • Kazuyoshi Kawabata, MD, PhD

      Affiliations

    • Division of Head and Neck, Cancer Institute Hospital, Tokyo, Japan

,Accepted 2 October 2009.

References 

  1. Do MY, Rhee Y, Kim DJ, Kim CS, Nam KH, Ahn CW, et al. Clinical features of bone metastases resulting from thyroid cancer: a review of 28 patients over a 20-year period. Endocr J. 2005;52:701–707
  2. Sugitani I, Fujimoto Y. Symptomatic versus asymptomatic papillary thyroid microcarcinoma: a retrospective analysis of surgical outcome and prognostic factors. Endocr J. 1999;46:209–216
  3. Sakamoto A, Kasai N, Sugano H. Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high-risk group of papillary and follicular carcinomas. Cancer. 1983;52:1849–1855
  4. Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A. A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery. 2004;135:139–148
  5. Fujimoto Y, Sugitani I. Postoperative prognosis of intrathyroidal papillary thyroid carcinoma: long-term (35–45 year) follow-up study. Endocr J. 1998;45:475–484
  6. Fujimoto Y, Obara T, Ito Y, Kodama T, Yashiro T, Yamashita T, et al. Aggressive surgical approach for locally invasive papillary carcinoma of the thyroid in patients over forty-five years of age. Surgery. 1986;100:1098–1107
  7. Sugitani I, Kamata S, Kawabata K, Kasai N, Fujimoto Y. Total pharyngo-laryngectomy and reconstruction of cervical esophagus with a jejunal free flap for locally advanced differentiated thyroid carcinoma. Thyroidol Clin Exp. 1998;10:249–253
  8. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Eng J Med. 1998;338:297–306
  9. Marcocci C, Pacini F, Elisei R, Schipani E, Ceccarelli C, Miccoli P, et al. Clinical and biologic behavior of bone metastases from differentiated thyroid carcinoma. Surgery. 1989;106:960–966
  10. Pittas AG, Adler M, Fazzari M, Tickoo S, Rosai J, Larson SM, et al. Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty six patients. Thyroid. 2000;10:261–268
  11. Proye CA, Dromer DH, Camaille BM, Gontier AJ, Goropoulos A, Carpentier P, et al. Is it still worthwhile to treat bone metastases from differentiated thyroid carcinoma with radioactive iodine?. World J Surg. 1992;16:640–646
  12. Shoup M, Stojadinovic A, Nissan A, Ghossein RA, Freedman S, Brennan MF, et al. Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. J Am Coll Surg. 2003;197:191–197
  13. Tickoo SK, Pittas AG, Adler M, Fazzari M, Larson SM, Robbins RJ, et al. Bone metastases from thyroid carcinoma. A histopathologic study with clinical correlates. Arch Pathol Lab Med. 2000;124:1440–1447
  14. Schlumberger M, Challeton C, De Vathaire F, Travagli JP, Gardet P, Lumbroso JD, et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med. 1996;37:598–605
  15. Harness JK, Thompson NW, McLeod MK, Eckhauser FE, Lloyd RV. Follicular carcinoma of the thyroid gland: Trends and treatment. Surgery. 1984;96:972–980
  16. Hindie E, Zanotti-Fregonara P, Keller I, Duron F, Devaux JY, Calzada-Nocaudie M, et al. Bone metastases of differentiated thyroid cancer: impact of early 131I-based detection on outcome. Endocr Relat Cancer. 2007;14:799–807
  17. Yamashita H, Fujimoto Y, Kodama T, Hirayama A, Obara T, Ito Y, et al. When is total thyroidectomy indicated as a treatment of “follicular carcinoma”?. World J Surg. 1988;12:559–564
  18. Sugitani I, Fujimoto Y, Yamamoto N. Papillary thyroid carcinoma with distant metastases: survival predictors and the importance of local control. Surgery. 2008;143:35–42
  19. Haq M, Harmer C. Differentiated thyroid carcinoma with distant metastases at presentation: prognostic factors and outcome. Clin Endocrinol. 2005;63:87–93
  20. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. Long term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocr Metab. 2006;91:2892–2899
  21. Bernier MO, Leenhardt L, Hoang C, Aurengo A, Mary JY, Menegaux F, et al. Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. J Clin Endocr Metab. 2001;86:1568–1573
  22. Koizumi M, Ogata E. Bone metabolic markers as gauges of metastasis to bone: a review. Ann Nucl Med. 2002;16:161–168
  23. Schlumberger M, Tubiana M, De Vathaire F, Hill C, Gardet P, Travagli JP, et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab. 1986;63:960–967
  24. Ito S, Kato K, Ikeda M, Imano S, Makino N, Tadokoro M, et al. Comparison of 18F-FDG PET and bone scintigraphy in detection of bone metastases of thyroid cancer. J Nucl Med. 2007;48:889–895
  25. Sugitani I, Yanagisawa A, Shimizu A, Kato M, Fujimoto Y. Clinicopathologic and immunohistochemical studies of papillary thyroid microcarcinoma presenting with cervical lymphadenopathy. World J Surg. 1998;22:731–737
  26. Hay ID, Grant CS, van Heerden JA, Goellner JR, Ebersold JR, Bergstralh EJ. Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period. Surgery. 1992;112:1139–1147
  27. Allo MD, Christianson W, Koivunen D. Not all “occult” papillary carcinomas are “minimal”. Surgery. 1988;104:971–976
  28. Hammerberg KW. Surgical treatment of metastatic spine disease. Spine. 1992;17:1148–1153
  29. Cascinu S, Graziano F, Alessandroni P, Ligi M, Del Ferro E, Rossi D, et al. Different doses of pamidronate in patients with painful osteolytic bone metastases. Support Care Cancer. 1998;6:139–143
  30. Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer. 2004;100:2613–2621
  31. Santini D, Fratto ME, Vincenzi B, Galluzzo S, Tonini G. Zoledronic acid in the management of metastatic bone disease. Expert Opin Biol Ther. 2006;6:1333–1348
  32. Vitale G, Fonderico F, Martignetti A, Caraglia M, Ciccarelli A, Nuzzo V, et al. Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer. Brit J Cancer. 2001;84:1586–1590

PII: S0039-6060(09)00619-9

doi: 10.1016/j.surg.2009.10.009

Surgery
Volume 147, Issue 3 , Pages 424-431 , March 2010

Article Tools

* Image Usage & Resolution